Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

While significant advancements have been made in the available therapies for metastatic
non-small cell lung cancer (NSCLC), acquired resistance remains a major barrier to …

Cancer cells utilise several mechanisms to increase their survival and progression as well
as their resistance to anticancer therapy: deregulation of growth regulatory pathways by …

Cancer therapy has advanced from tradition chemotherapy methods to targeted therapy,
novel drug delivery mechanisms, combination therapies etc. Although several novel …

Cisplatin is one of the most potent anticancer agents, displaying significant clinical activity
against a variety of solid tumors. For more than two decades, the most effective systemic …

The effectiveness of chemotherapy is one of the main challenges in cancer treatment and
resistance to classic drugs and traditional treatment processes is an obstacle to this goal …

The major problem in lung cancer chemotherapy is the emergence of inherent and acquired
drug resistance of the cancer cells. Establishment of drug-resistant sublines and …

Drug resistance is a complex phenomenon that frequently develops as a failure to
chemotherapy during cancer treatment. Malignant cells increasingly generate resistance to …

Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer
(NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …